Proprio vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 53)
Proprio logo

Proprio

ChallengerHealthcare

Surgical Navigation & AI

Proprio builds the Paradigm AI surgical guidance platform, providing radiation-free 3D real-time anatomy visualization and intraoperative spinal alignment measurements for spine surgeons.

AI VisibilityBeta
Overall Score
C53
Category Rank
#236 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
53
Gemini
56

About

Proprio is a Seattle-based surgical technology company founded in 2016 by CEO Gabriel Jones alongside neurosurgeon Dr. Samuel Browd, University of Washington Professor Joshua Smith, and computer vision specialist James Youngquist. The company develops Paradigm, an FDA-cleared AI surgical guidance platform that uses light-field imaging, optical tracking, depth sensors, and infrared cameras to build a real-time 3D model of the surgical field without ionizing radiation.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

53
Overall Score
90
#236
Category Rank
#2
82
AI Consensus
83
stable
Trend
up
49
ChatGPT
92
53
Perplexity
93
56
Gemini
89
51
Claude
96
55
Grok
95

Key Details

Category
Surgical Navigation & AI
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.